These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 8826953

  • 1. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
    Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Fermé C.
    Cancer; 1996 Sep 15; 78(6):1293-9. PubMed ID: 8826953
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.
    Bone Marrow Transplant; 1997 Jul 15; 20(1):21-6. PubMed ID: 9232251
    [Abstract] [Full Text] [Related]

  • 3. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, Diehl V, Josting A.
    J Clin Oncol; 2007 May 20; 25(15):2000-5. PubMed ID: 17420510
    [Abstract] [Full Text] [Related]

  • 4. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM.
    Bone Marrow Transplant; 2001 Feb 20; 27(4):387-96. PubMed ID: 11313668
    [Abstract] [Full Text] [Related]

  • 5. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I, Ganser D, Freitag EM, Bohndorf W.
    Strahlenther Onkol; 1994 Sep 20; 170(9):516-23. PubMed ID: 7524173
    [Abstract] [Full Text] [Related]

  • 6. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep 20; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 7. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
    Gao Y, Huang HQ, Lin XB, Cai QQ, Pan ZH, Wang BF, Bu Q.
    Ai Zheng; 2007 Aug 20; 26(8):909-13. PubMed ID: 17697558
    [Abstract] [Full Text] [Related]

  • 8. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY, Hu DS, Zeng FY, Song QB, Hu S, Wei L, Zhou LQ.
    Ai Zheng; 2007 Dec 20; 26(12):1360-4. PubMed ID: 18076802
    [Abstract] [Full Text] [Related]

  • 9. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J.
    Biol Blood Marrow Transplant; 1997 Jun 20; 3(2):98-106. PubMed ID: 9267670
    [Abstract] [Full Text] [Related]

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 20; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 11. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM, Anselmo AP, Donato V, Falchetto Osti M, Santoro M, Tombolini V, Mandelli F.
    Haematologica; 1999 Oct 20; 84(10):917-23. PubMed ID: 10509040
    [Abstract] [Full Text] [Related]

  • 12. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A.
    J Clin Oncol; 2005 Mar 01; 23(7):1522-9. PubMed ID: 15632410
    [Abstract] [Full Text] [Related]

  • 13. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun 01; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 14. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
    Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, Agarwal R.
    J Clin Oncol; 2004 Nov 15; 22(22):4532-40. PubMed ID: 15542804
    [Abstract] [Full Text] [Related]

  • 15. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec 15; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy.
    Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, Billett A, Marcus KJ, Tarbell NJ, Donaldson SS.
    J Clin Oncol; 2003 May 15; 21(10):2026-33. PubMed ID: 12743158
    [Abstract] [Full Text] [Related]

  • 17. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
    Sureda A, Mataix R, Hernández-Navarro F, Jarque I, Lahuerta JJ, Tomás JF, Brunet S, Caballero D, Conde E, León A, Fernández MN, López A, Maldonado J, Bengoechea E, Callís M, Carrera D, García-Conde J, García-Laraña J, Moraleda JM, Morey M, Rifón J, Sierra J, Torres A, Domingo-Albós A.
    Bone Marrow Transplant; 1997 Aug 15; 20(4):283-8. PubMed ID: 9285542
    [Abstract] [Full Text] [Related]

  • 18. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, Radford JA.
    Bone Marrow Transplant; 1999 Aug 15; 24(3):271-7. PubMed ID: 10455365
    [Abstract] [Full Text] [Related]

  • 19. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.
    Ai Zheng; 2006 Aug 15; 25(8):1013-8. PubMed ID: 16965685
    [Abstract] [Full Text] [Related]

  • 20. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 15; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.